Hervé Lefevre1, Stéphanie Samain2, Nour Ibrahim3, Christine Fourmaux4, Anne Tonelli5, Sébastien Rouget6, Emmanuelle Mimoun7, Renaud De Tournemire8, Marie Devernay9, Marie Rose Moro10, Jonathan Lachal11. 1. AP-HP, Cochin Hospital, Maison de Solenn, Paris, France; CESP, Fac. de médecine - Univ. Paris-Sud, Fac. de médecine - UVSQ, INSERM, Université Paris-Saclay, 94805 Villejuif, France; French Clinical Research Group in Adolescent Medicine and Health, France. Electronic address: herve.lefevre@aphp.fr. 2. AP-HP, Cochin Hospital, Maison de Solenn, Paris, France; Université Paris Descartes, Sorbonne Paris Cité, Paris, France. 3. AP-HP, Cochin Hospital, Maison de Solenn, Paris, France; CESP, Fac. de médecine - Univ. Paris-Sud, Fac. de médecine - UVSQ, INSERM, Université Paris-Saclay, 94805 Villejuif, France; French Clinical Research Group in Adolescent Medicine and Health, France; Université Paris Descartes, Sorbonne Paris Cité, Paris, France. Electronic address: nour.ibrahim@aphp.fr. 4. French Clinical Research Group in Adolescent Medicine and Health, France; Unité de médecine de l'adolescent CHI Créteil, France. Electronic address: christine.Fourmaux@chicreteil.fr. 5. French Clinical Research Group in Adolescent Medicine and Health, France; Service de médecine interne pour adolescence, clinque E.Rist, Paris, France. Electronic address: anne.tonelli@fsef.net. 6. French Clinical Research Group in Adolescent Medicine and Health, France; Service de pédiatrie Centre Hospitalier Sud-Francilien, Corbeil, France. Electronic address: sebastien.rouget@chsf.fr. 7. French Clinical Research Group in Adolescent Medicine and Health, France; CH Marchant, Toulouse, France. Electronic address: emmanuelle.mimoun@ch-marchant.fr. 8. French Clinical Research Group in Adolescent Medicine and Health, France; Unité de Médecine pour Adolescents CHI Poissy St Germain en Laye, France. Electronic address: rdetournemire@chi-poissy-st-germain.fr. 9. French Clinical Research Group in Adolescent Medicine and Health, France; AP-HP, Trousseau Hospital, unité pour adolescents, Paris France. Electronic address: marie.devernay@aphp.fr. 10. AP-HP, Cochin Hospital, Maison de Solenn, Paris, France; CESP, Fac. de médecine - Univ. Paris-Sud, Fac. de médecine - UVSQ, INSERM, Université Paris-Saclay, 94805 Villejuif, France; Université Paris Descartes, Sorbonne Paris Cité, Paris, France. Electronic address: marie-rose.moro@aphp.fr. 11. AP-HP, Cochin Hospital, Maison de Solenn, Paris, France; CESP, Fac. de médecine - Univ. Paris-Sud, Fac. de médecine - UVSQ, INSERM, Université Paris-Saclay, 94805 Villejuif, France; Université Paris Descartes, Sorbonne Paris Cité, Paris, France. Electronic address: jonathan.lachal@gmail.com.
Abstract
OBJECTIVE: Vaccination coverage against HPV in France is among the lowest in the industrialized world, although the public authorities have recently become aware of this issue. Few studies have looked at teenaged girls' representations of this vaccination, even though they are the most concerned by it. This qualitative study explored the experiences and representations of HPV vaccination by adolescent girls seeing doctors at least occasionally. STUDY DESIGN: We used a written essay question to explore this issue among 101 adolescent girls at six urban medical centers and a semi-structured interview to discuss it in further depth with five of them. The analysis was lexicometric (ALCESTE®) and phenomenological (Interpretative Phenomenological Analysis). RESULTS: These results are organized around four superordinate themes: the teenage girls' factual knowledge about this vaccine, their motives for and obstacles to vaccination, their involvement in this decision, and finally the need for information about and solutions to this issue. CONCLUSIONS: Teenage girls know little about this vaccine and are more sensitive to the emotional discourse that surrounds it than to rational knowledge about it. The requirement for parental authorization for this vaccine reinforces the girls' lack of investment. Vaccination programs should integrate the HPV vaccine more thoroughly into general prevention concerning sexual health and should send a strong signal by offering minors anonymous vaccination free of charge, as is already the case in France for requests for contraception, the morning-after pill, elective abortion, and screening and treatment of sexually transmitted infections.
OBJECTIVE: Vaccination coverage against HPV in France is among the lowest in the industrialized world, although the public authorities have recently become aware of this issue. Few studies have looked at teenaged girls' representations of this vaccination, even though they are the most concerned by it. This qualitative study explored the experiences and representations of HPV vaccination by adolescent girls seeing doctors at least occasionally. STUDY DESIGN: We used a written essay question to explore this issue among 101 adolescent girls at six urban medical centers and a semi-structured interview to discuss it in further depth with five of them. The analysis was lexicometric (ALCESTE®) and phenomenological (Interpretative Phenomenological Analysis). RESULTS: These results are organized around four superordinate themes: the teenage girls' factual knowledge about this vaccine, their motives for and obstacles to vaccination, their involvement in this decision, and finally the need for information about and solutions to this issue. CONCLUSIONS: Teenage girls know little about this vaccine and are more sensitive to the emotional discourse that surrounds it than to rational knowledge about it. The requirement for parental authorization for this vaccine reinforces the girls' lack of investment. Vaccination programs should integrate the HPV vaccine more thoroughly into general prevention concerning sexual health and should send a strong signal by offering minors anonymous vaccination free of charge, as is already the case in France for requests for contraception, the morning-after pill, elective abortion, and screening and treatment of sexually transmitted infections.
Authors: Vita W Jongen; Maarten F Schim van der Loeff; Anders Boyd; Mariska Petrignani; Maria Prins; Marcel van der Wal; Astrid Nielen; Hester de Melker; Theo G W M Paulussen; Catharina J Alberts Journal: Hum Vaccin Immunother Date: 2020-09-23 Impact factor: 3.452
Authors: Cristyn Davies; Helen S Marshall; Gregory Zimet; Kirsten McCaffery; Julia M L Brotherton; Melissa Kang; Suzanne Garland; John Kaldor; Kevin McGeechan; S Rachel Skinner Journal: JAMA Netw Open Date: 2021-11-01